Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.

ABSTRACT:

Objective

Evaluate the efficacy, safety, and tolerability of zavegepant nasal spray in the acute treatment of migraine.

Background

Calcitonin gene-related peptide-targeting agents are a novel class of therapeutics for migraine, but none are currently available as a nonoral option for acute treatment. Zavegepant, a high-affinity, selective, and structurally unique calcitonin gene-related peptide-receptor antagonist in late-stage development, is formulated as a nasal spray for the acute treatment of migraine.

Methods

This randomized, dose-ranging, placebo-controlled, Phase 2/3 trial in adults aged ≥18 years with migraine (NCT03872453) was conducted at US study sites. Participants were randomized by an interactive web response system and treated a single attack of modera

SUBMITTER: Croop R 

PROVIDER: S-EPMC9827820 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature